Name: Mavorixafor
Brand: Selleck Chemicals
SKU: E1318
Availability: InStock
Rating: 5 (1 reviews)

Jump to

Quality Control

Batch: E131801 DMSO]70 mg/mL]false]Ethanol]70 mg/mL]false]Water]Insoluble]false Purity: 99.08%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS/MSDS
Datasheet

99.08

Related Targets	Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas GPR
Other CXCR Inhibitors	AZD5069 SB 225002 Reparixin (Repertaxin) WZ811 Navarixin (SCH-527123) LIT-927 AMG 487 SX-682 SB 265610 LY2510924

Solubility

In vitro
Batch:

DMSO : 70 mg/mL (200.3 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 70 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.500mg/ml (10.02mM)	Taking the 1 mL working solution as an example, add 50 μL of 70 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.750mg/ml (5.01mM)	Taking the 1 mL working solution as an example, add 50 μL of 35 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	349.47	Formula	C₂₁H₂₇N₅	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	558447-26-0	Download SDF		Storage of Stock Solutions	Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.

Read more about storage stability CAS number

Mechanism of Action

Targets/IC₅₀/Ki	CXCR4 13 μM
References	[1] https://pubmed.ncbi.nlm.nih.gov/20297846/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-06)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06056297	RECRUITING	Neutropenia	X4 Pharmaceuticals	2024-06-06	PHASE3
NCT06858696	COMPLETED	Hepatic Insufficiency	X4 Pharmaceuticals	2025-02-28	PHASE1
NCT03995108	COMPLETED	WHIM Syndrome	X4 Pharmaceuticals	2019-10-24	PHASE3
NCT06914869	COMPLETED	Healthy Participants	X4 Pharmaceuticals	2025-02-18	PHASE1
NCT04154488	COMPLETED	Neutropenia	X4 Pharmaceuticals	2021-10-16	PHASE1; PHASE2
NCT04274738	COMPLETED	Waldenstrom's Macroglobulinemia	X4 Pharmaceuticals	2020-04-30	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Mavorixafor CXCR antagonist

Chemical Structure

Molecular Weight: 349.47